SOURCE: Rothman Research

Rothman Research

March 10, 2010 09:31 ET

Drug Manufacturing Companies Are Committed to Various R&D to Supply the Rise in Demand for Chronic Health Conditions

JOHANNESBURG, SOUTH AFRICA--(Marketwire - March 10, 2010) -

Most Pharmaceutical Companies are up and about in discovery and development of contemporary drugs for treatments of various diseases. They are frequently initiating clinical trials to provide quality treatments to patients and therapeutic solutions for medical representatives, and health care providers. "The companies pushing their efforts in R&D are flourishing in the market," says Mathew Collier of, "and these companies are doing their best to honor what the public demands from them -- quality patient care." studied companies with high-level-commitment in providing quality patient care through R&D. Two companies stand out in their recent reports -- Somaxon Pharmaceuticals Inc. (NASDAQ: SOMX) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Sign up for free now at and get access to those reports

 *Click on the following links to view the PDF version of the intensive research reports:   or

Investors are excited about certain pharmaceutical companies with a possible variable approach in the market and of them is Vertex Pharmaceuticals. Big pharmaceutical companies are expected to engulf mid-to-large cap biotechnologies this year.

* is a source for investors seeking free information on pharmaceutical stocks; investors are encouraged to sign up for free at

To be a leading specialty pharmaceutical company is the goal of Somaxon Pharmaceuticals Inc. The company is focused on the development and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system.

In the recent news, Vertex Pharmaceuticals Incorporated announced that it is initiating the first clinical trial evaluating new preparations of drugs for treating Hepatitis C Virus (HCV). "Vertex is committed to improving patient care in HCV, and the announcement of this clinical trial combining two oral agents signifies our first exploration into this combination regimen's potential role to further improve the treatment of HCV," said Peter Mueller, Ph.D., Vertex's Chief Scientific Officer and Executive Vice President, Global Research and Development.

Visit to read about pharmaceutical companies and their impact in the stock market today.

To learn more about other investment opportunities, log on to for a free research report, to help you make the right decision.

Companies looking for additional media or advertising services can call Blue Chip IR at 1-917-267-8836

About Rothman Research

Rothman Research brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities.

Contact Information